Immunic AG | Finanzwire

Basculer en Français

8298	Companies
114933	Keywords
55342	Articles
62466	Press releases

Home
Companies
Immunic AG

BRIEF

published on 09/18/2024 at 12:35, 2 months 3 days ago

Immunic Unveils Promising Vidofludimus Calcium Data at ECTRIMS Congress

Multiple Sclerosis Immunic Vidofludimus Calcium Neuroprotection ECTRIMS 2024
PRESS RELEASE

published on 09/18/2024 at 12:30, 2 months 3 days ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark

Multiple Sclerosis Immunic Vidofludimus Calcium Therapeutic Potential ECTRIMS
BRIEF

published on 09/04/2024 at 12:35, 2 months 17 days ago

Immunic Enrolls First Patient in Phase 2 Trial for Post COVID Syndrome

Clinical Trial Vidofludimus Calcium Post COVID Syndrome Fatigue Treatment Epstein-Barr Virus
PRESS RELEASE

published on 09/04/2024 at 12:30, 2 months 17 days ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Immunic announces enrollment of the first patient in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium for Post COVID Syndrome. Study aims to suppress EBV reactivation and fatigue symptoms

Clinical Trial Immunic Vidofludimus Calcium Phase 2 Post COVID Syndrome
BRIEF

published on 08/28/2024 at 12:35, 2 months 24 days ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Multiple Sclerosis Immunic Vidofludimus Calcium R&D Day Scientific Conferences
PRESS RELEASE

published on 08/28/2024 at 12:30, 2 months 24 days ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
Immunic to host Multiple Sclerosis R&D Day & participate in conferences. Immunic, Inc. develops oral therapies for autoimmune diseases

Investor Conferences Multiple Sclerosis Immunic R&D Day Scientific Conferences
BRIEF

published on 08/08/2024 at 12:35, 3 months 13 days ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Financial Results Biotechnology Clinical Trials Multiple Sclerosis Immunic
PRESS RELEASE

published on 08/08/2024 at 12:30, 3 months 13 days ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q2 2024 financial results and corporate update, appoints new COO & strengthens BOD. Webcast on August 8. Ongoing trials remain on track

Financial Results Clinical Trials Corporate Update Immunic Inc. COO Appointment
BRIEF

published on 08/01/2024 at 12:35, 3 months 20 days ago

Immunic, Inc. to Announce Financial Results for Q2 2024 and Provide Corporate Update

Biotechnology Clinical Trials Webcast Immunic, Inc. Q2 Financial Results
PRESS RELEASE

published on 08/01/2024 at 12:30, 3 months 20 days ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
Immunic, Inc. to announce Q2 2024 financial results and corporate update on August 8, 2024, including webcast participation details. Company developing therapies for inflammatory diseases

Financial Results Webcast Immunic Inc. Q2 2024 Inflammatory Diseases

Accesswire

Published on 11/21/2024 at 14:00, 14 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 14 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 14 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 14 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report
Published on 11/21/2024 at 13:30, 44 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:00, 14 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 59 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 39 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 59 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 2 hours 8 minutes ago

IVU AG publishes Quarterly Report Q3-2024

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 16 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 54 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 29 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 29 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE